Stock DNA
Pharmaceuticals & Biotechnology
INR 843 Cr ()
31.00
34
0.00%
0.00
0.00%
3.96
Total Returns (Price + Dividend) 
Anlon Healthcare for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Invitation For TV Interview On NDTV Profit.
11-Jun-2026 | Source : BSEWe have attached herewith intimation as per Regulation 30 of SEBI (LODR) Regulation 2015. Kindly take the same on your record. Thank you.
Intimation Regarding Media Interaction Of Chairman & Managing Director
09-Jun-2026 | Source : BSEWe have attached herewith intimation as per Regulation 30 of SEBI (LODR) Regulation 2015. Kindly take the same on your record. Thank you.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
09-Jun-2026 | Source : BSEWe have attached herewith earning call transcript as per Regulation 30 of SEBI (LODR) Regulation 2015. Kindly take the same on your record. Thank you.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
Anlon Healthcare Ltd has announced 2:10 stock split, ex-date: 24 Apr 26
Anlon Healthcare Ltd has announced 1:1 bonus issue, ex-date: 24 Apr 26
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 5 FIIs (0.32%)
Punitkumar R Rasadia (34.98%)
Shree Dwarikadhish Ventures Llp (7.53%)
24.38%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 55.76% vs -31.84% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 90.10% vs -44.74% in Dec 2025
Annual Results Snapshot (Standalone) - Mar'26
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period